2 documents found, page 1 of 1
Open-label phase 3 study of intravenous golimumab in patients with polyarticula...
Ruperto, Nicolino; Brunner, Hermine; Pacheco-Tena, Cesar; Louw, Ingrid; Vega-Cornejo, Gabriel; Spindler, Alberto J.; Kingsbury, Daniel J.Made available in DSpace on 2022-04-28T17:22:32Z (GMT). No. of bitstreams: 0 Previous issue date: 2021-10-01; Janssen Research & Development, LLC; Objectives. To assess efficacy, pharmacokinetics (PK) and safety of intravenous (i.v.) golimumab in patients with polyarticular-course JIA (pc-JIA). Methods. Children aged 2 to <18 years with active pc-JIA despite MTX therapy for >= 2months received 80 mg/m(2) golimu...
Open-label phase 3 study of intravenous golimumab in patients with polyarticula...
Ruperto, Nicolino; Brunner, Hermine I; Pacheco-Tena, César; Louw, Ingrid; Vega-Cornejo, Gabriel; Spindler, Alberto J; Kingsbury, Daniel JMade available in DSpace on 2022-04-29T08:30:48Z (GMT). No. of bitstreams: 0 Previous issue date: 2021-10-01; Objectives: To assess efficacy, pharmacokinetics (PK) and safety of intravenous (i.v.) golimumab in patients with polyarticular-course JIA (pc-JIA). Methods: Children aged 2 to <18 years with active pc-JIA despite MTX therapy for ≥2 months received 80 mg/m2 golimumab at weeks 0, 4, then every 8 weeks th...